A strong week for brain-computer interface (BCI) companies, who attracted massive support from investors. Syncron’s round featured heavyweight investors including Bezos Expeditions and Qatar Investment Authority, who are attracted by their approaching commercial viability. The rise of telemedicine is also signalled by Sovato’s strong round, suggesting the future of surgery can be very different from what we see today.
Synchron Raises $200 Million Series D to advance BCI tech
The funding will accelerate commercialisation of the company’s first-generation Stentrode BCI platform, while advancing development of a frontier next-generation interface.
The round was led by Double Point Ventures, alongside existing investors ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI and METIS. New investors include the Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT. The financing brings Synchron’s total funding to $345 million.
CEO Tom Oxley
Last week’s tracker: VentureMed, Optiscan and more
Sovato raises Series B funds to advance remote robotic surgery platform
Led by VC business Beringea, the round brings Sovato’s funding to date to $41m. Other participating investors included Teladoc Health, GS Ventures, and Laerdal Million Lives Fund.
The latest round will support the development of its platform, along with forging new strategic partnerships with entities, including surgical robotics companies, healthcare providers, and related ecosystem collaborators.
Co-founder and CEO Cynthia Perazzo
Precision Neuroscience gains investment from paralysis-focused VC
BCI leader Precision Neuroscience received an investment from SCI Ventures, a VC firm that claims to hold the world’s first specialist fund dedicated to addressing paralysis.
The Layer 7 Cortical Interface is primarily being developed to restore communication and control for people with paralysis.
CEO Michael Mager
Coherence Neuro raises $10M seed round for BCI that aids in cancer treatment
The funding supports the company’s flagship SOMA-1 device – a therapeutic brain-computer interface that continually monitors and administers custom stimulation to potentially treat cancer.
The seed round was led by Artesian & Topology Ventures. Pre-seed investors Blackbird and Possible Ventures also participated, as well as other investors and angels.
Co-founders Elise Jenkins and Ben Woodington
Beyond Air secures Up to $32 Million of funding
It entered into financing agreements with Streeterville Capital, providing up to $32 million in total potential proceeds. Under the terms of the agreement, Beyond Air issued a $12 million promissory note to Streeterville Capital, bearing a 15% annual interest rate.
The infusion provides flexibility to accelerate their commercial expansion, aimed at driving sales growth for LungFit PH.
Chairman and CEO Steve Lisi
